Previous 10 | Next 10 |
Pacira BioSciences (NASDAQ:PCRX) has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for claims of chemical composition of Exparel (bupivacaine liposome injectable suspension). After issuance, Pacira will submit the patent for listing in the FDA...
-- Patent eligible for Orange Book listing will provide additional protection into 2041 -- TAMPA, Fla., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, t...
PARSIPPANY, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday, November 3, 2021. Following the release, the company will host a live conferen...
Potential deal in the works Aspen Technology materializes. Two deals with Contingent Value Rights announced last week. Navios Maritime Partners completed the acquisition of Navios Maritime Acquisition Corporation. For further details see: Merger Arbitrage Mondays: Emerso...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This Monday seems to be a lucrative one for investors in biopharmaceutical companies. It seems like everybody has some good news to report, whether that be optimistic trial data or a successful merger or acquisition. Flexi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re kicking off the week with a look at the biggest pre-market stock market movers for Monday! Source: f11photo/Shutterstock.com There’s plenty of news moving stock today with ...
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accr...
TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to ap...
Shares of Pacira BioSciences (NASDAQ: PCRX) were sinking 12.7% as of 3:33 p.m. EDT on Monday. The decline came after the company announced that eVenus Pharmaceutical Laboratories is seeking Food and Drug Administration approval for a generic version of non-opioid pain drug Exparel. ...
TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has received a Paragraph IV Certification Notice Letter advising that eVenus Pharmaceutical Laborato...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...